Opioid Litigation – The Defense Perspective [Download Conference Presentation Slides]

Posted by on April 23, 2018

The opioid litigation landscape continues to evolve, with over 200 lawsuits currently consolidated in the multidistrict litigation (MDL), In re: National Prescription Opiate Litiga­tion, MDL No. 2804, in the Northern Dis­trict of Ohio and being overseen by U.S. District Court Judge Dan Polster. New opioid cases continue to be filed (inside and outside of the
Read More

Unverified Science-Based Claims in the Media – Another Example Why the “Ingelfinger Rule” is so Important

Posted by on March 19, 2018

It’s likely that most readers of this blog, let alone most members of the public, have little idea of what the Ingelfinger Rule is and less about why it is so important. First promulgated in-house by the New England Journal of Medicine in 1969, the rule stipulated that the editors would not accept findings that
Read More

How to Find the Right Regulatory Experts for Your Case or Controversy

Posted by , and on March 13, 2018

Whether you are outside counsel retained in a pharmaceutical product liability case or in-house counsel responsible for a chemical manufacturer in a high-profile government investigation, having the right regulatory expert can be the difference between remarkable success and high stakes failure. What should you look for in an expert? In selecting the best regulatory expert,
Read More

The Importance of Genetics Experts in Pharmaceutical Litigation

Posted by on March 6, 2018

A Case Study from the Testosterone Litigation A recent defense verdict in the testosterone litigation highlights the importance of genetics in pharmaceutical litigation. In this case, neither the plaintiffs nor the defense called a geneticist as an expert, yet both sides tried to use genetic arguments in their case. In this post we summarize the
Read More

Protein-based adverse drug reactions (ADRs): Using proteomics to assess drug safety

Posted by on February 20, 2018

Each year, adverse drug events cost millions of dollars in hospital admissions, injuries to patients, and malpractice. And companies spend billions of dollars on litigation involving allegations that their drugs caused adverse drug reactions (ADRs). What if there was a better way to determine individualized drug adverse events? Welcome to the Age of Proteomics The
Read More

Do You Have the Right Scientific and Technical Support To Succeed In Biopharmaceutical Patent Litigation?

Posted by on February 9, 2018

This post was authored by David H. Schwartz, a principle at Innovative Science Solutions and Paul Fehlner, JD, PhD, founder of Life Sciences Innovation. Paul is a life sciences lawyer and biopharmaceutical consultant with a strong intellectual property focus who partners with research institutes, startups, and Fortune 500’s to help them transform basic scientific discoveries
Read More

Using Big Data Tools To Help Build Great Expert Teams

Posted by and on January 30, 2018

As a litigator specializing in product liability, toxic torts, government actions and other civil litigation, identifying the right experts and recruiting a team of experts perfectly suited to your case can be critical to your success, especially when that case involves complex scientific issues. Different Types of Expert Disciplines For example, in cases that involve
Read More

Human-Organs-on-Chips: Will They Revolutionize Courtroom Toxicology Testimony?

Posted by on January 25, 2018

Human-Organs-on-Chips are microfluidic cell culture microchips lined with living human cells that simulate the functions of human organs, including the lung, intestine, kidney, skin, bone marrow and blood-brain barrier. Engineered by Dr. Donald Ingber and Wyss Institute researchers in 2010, these microchips have the potential to revolutionize drug development, disease modeling, and personalized medicine. But
Read More

Mitigating the Risk of Adverse Drug Reactions in Pharmacogenomic-Inspired Litigation

Posted by on January 11, 2018

This post was drafted by Innovative Science Solutions and Wendell S. Fortson, founder of Fortson Strategies, LLC.  Fortson Strategies is a national cancer litigation strategy firm for corporations. The firm’s focus is oncology-related matters involving patent, toxic torts and products liability litigation. It is well-established that not every individual responds the same way to a
Read More

Toxicology in the 21st Century – 5 Tips for Litigators

Posted by on January 3, 2018

Chemicals are part of everyday life. They are found in common household and workplace products including food, packaging, paint and dyes, cleaning supplies, medicines, among many other categories of products. Yet, only a small number of chemicals have been thoroughly assessed for their potential toxicity in humans. Furthermore, there are an increasing number of commercially
Read More